| Abstrakt: |
A study conducted by researchers at Hunan University of Chinese Medicine in China has found that liposomal silybin (SLB) can improve glucose and lipid metabolisms in individuals with type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease (T2DM-NAFLD). SLB, which has potential hepatoprotective properties, was encapsulated in liposomes and administered to a rat model of T2DM-NAFLD. The results showed that liposomal SLB alleviated insulin resistance, improved lipid metabolism, and reduced hepatic damage, inflammation, and fibrosis. The study suggests that liposomal SLB activates the AMPK/TGF-β1/Smad pathway, providing a potential treatment strategy for T2DM-NAFLD. [Extracted from the article] |
